Journey Medical (DERM) Cost of Revenue (2020 - 2026)

Journey Medical (DERM) has reported Cost of Revenue for 7 consecutive years, with $6.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 24.38% year-over-year to $6.1 million; the trailing twelve-month figure through Jun 2026 stood at $23.6 million (up 24.77% YoY), and the FY2025 full-year result was $20.9 million, changed 0.22% from the prior year.
• Cost of Revenue retreated to $6.1 million in Q2 2026 per DERM's latest filing, from $6.2 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $8.2 million in Q1 2022 and bottomed at $2.2 million in Q4 2023.
• Historically, Cost of Revenue has averaged $6.0 million across 5 years, with a median of $6.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue surged 109.9% in 2022, then sank 70.87% in 2023.
• Over 5 years, Cost of Revenue stood at $7.7 million in 2022, then tumbled by 70.87% to $2.2 million in 2023, then surged by 108.19% to $4.7 million in 2024, then increased by 16.24% to $5.4 million in 2025, then advanced by 12.92% to $6.1 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $6.1 million, $6.2 million, and $5.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.